注冊以創建關於儀器的通知
你所追隨的作者的經濟活動和內容
免費註冊 已有帳戶? 登入
TFF Pharmaceuticals Inc是一家臨床階段的生物製藥公司,專注於基於其專利薄膜冷凍(TFF)技術平台開發和商業化創新藥物產品。TFF平台旨在提高水溶性差的藥物的溶解度和吸收性,尤其適用於生成具有針對吸入遞送特性的干粉顆粒,特別是針對深肺這一呼吸醫學領域極為感興趣的領域。TFF Pharmaceuticals有兩種主要候選藥物:吸入伏立康唑粉(TFF Vori)和吸入他克莫司粉(TFF Tac-Lac)。該公司正在與Augmenta BioWorks合作開發吸入性SARS-CoV2單克隆抗體,並在合作協議中參與開發氯硝柳胺的干粉製劑。它還通過局部、眼部和鼻部應用積極參與多種藥物和疫苗的干粉製劑的分析和測試。
名稱 | 年齡 | 成立於 | 主旨 |
---|---|---|---|
Anthony J. Hickey | - | 2022 | Chairman of the Scientific Advisory Board and Senior Research & Development Advisor |
David N. Cornfield | - | 2021 | Member of Scientific Advisory Board |
Stephen Charles Rocamboli | 51 | 2018 | Independent Director |
Ted M. Ross | - | 2021 | Member of Scientific Advisory Board |
Drew Weissman | - | 2021 | Member of Scientific Advisory Board |
Mike Saag | - | 2021 | Member of Scientific Advisory Board |
Robert S. Mills | 70 | 2018 | Independent Director |
Harlan F. Weisman | 71 | 2018 | President, CEO & Director |
Jay Peters | - | 2021 | Member of Scientific Advisory Board |
David W. Denning | - | 2021 | Member of Scientific Advisory Board |
Brandi L. Roberts | 49 | 2022 | Independent Director |
Michael A. Patane | 59 | 2023 | Independent Director |
Thomas B. King | 69 | 2023 | Independent Director |
Catherine C. Lee | 50 | 2023 | Independent Director |
你確定要封鎖 %USER_NAME%?
此舉將會令你與 %USER_NAME% 之間無法看見對方的Investing.com貼文。
%USER_NAME% 已成功加入你的封鎖清單
你剛解除此人的封鎖,必須等候 48 小時後才可再次封鎖。
我覺得這個評論是:
謝謝!
您的報告已被發送到我們的版主審核